Compare key investment metrics of 대원제약 and 유유제약 in real time. Both stocks belong to the 스테로이드 관련주 sector. View PER (Price-to-Earnings Ratio), PBR (Price-to-Book Ratio), dividend yield, market capitalization, and 52-week high/low side by side, with automatic highlighting of the leading stock for each metric.
Comparison at a Glance
- For dividend-focused investors, 대원제약 has the edge — dividend yield 3.14% vs 유유제약's 3.03%.
- By market capitalization, 대원제약 is larger — ₩179B vs 유유제약's ₩60B. Larger companies tend to be less volatile, while smaller ones may offer more growth headroom.
- 대원제약's current price of 7,970원 sits at about 11% of its 52-week range (7,200원–14,000원).
- 유유제약's current price of 3,800원 sits at about 15% of its 52-week range (3,575원–5,100원).
- This comparison is for reference only, based on publicly available market data, and does not constitute investment advice.
| Metric | 대원제약 | 유유제약 |
|---|---|---|
| Price | 7,970원 | 3,800원 |
| PER | - | 8.24배 |
| PBR | 0.65배 | 0.53배 |
| Dividend Yield | 3.14% | 3.03% |
| Market Cap | ₩179B | ₩60B |
| 52-Week High | 14,000원 | 5,100원 |
| 52-Week Low | 7,200원 | 3,575원 |
As of 2026-07-06 · Source: KRX (Naver Finance) public data
Frequently Asked Questions
Which has a lower PER, 대원제약 or 유유제약?
PER (Price-to-Earnings Ratio) divides a stock's price by its earnings per share. A lower PER may suggest the stock is undervalued relative to its earnings. Since PER changes with each earnings report, check the real-time comparison table on this page for the latest 대원제약 and 유유제약 PER values.
What is the dividend yield difference between 대원제약 and 유유제약?
As of 2026-07-06, 대원제약 offers the higher dividend yield — about 3.14% vs 유유제약's 3.03%. Dividend yield measures annual dividends as a percentage of the stock price and fluctuates with dividend policy and price movements.
How to compare 대원제약 and 유유제약?
PFlow's stock comparison page lets you compare key investment metrics side by side — PER, PBR, dividend yield, market cap, and 52-week high/low. Each metric automatically highlights which stock has the advantage. For deeper analysis, visit each stock's dedicated detail page.